X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration leverages Canary Speech's AI vocal biomarker platform which utilizes advanced AI algorithms to revolutionize the way Alzheimer's disease can be monitored and treated by integrating these insights to enhance the development and efficacy of its HT-4253 drug.
Lead Product(s): HT-4253
Therapeutic Area: Neurology Product Name: HT-4253
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Canary Speech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 06, 2024
Details:
HT-6184 is a first-in-class NLRP3-inhibitor which target the protein NEK7 through an allosteric mechanism. It is under phase 2 clinical development for the treatment of lower-risk myelodysplastic syndromes.
Lead Product(s): HT-6184
Therapeutic Area: Oncology Product Name: HT-6184
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023
Details:
HT-6184 is the first drug candidate to target the protein NEK7 through an allosteric mechanism to inhibit NLRP3 inflammasome activity and it promotes the disassembly of the inflammasome once activated.
Lead Product(s): HT-6184
Therapeutic Area: Neurology Product Name: HT-6184
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2023
Details:
HT-6184, is the first to target NEK7 through an allosteric mechanism. HT-6184 prevents the interaction of NEK7 with NLRP3, which blocks the formation of the NLRP3 inflammasome complex, an important driver of chronic inflammation.
Lead Product(s): HT-6184
Therapeutic Area: Cardiology/Vascular Diseases Product Name: HT-6184
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
HT-6184, novel small molecule inhibitor of NEK7 and NLRP3 pathway, is lead molecule from Halia's structure-based drug design strategy, which has produced pipeline of novel drug candidates targeting essential mediators of inflammation with potential to treat number of disease.
Lead Product(s): HT-6184
Therapeutic Area: Cardiology/Vascular Diseases Product Name: HT-6184
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2022
Details:
NLRP3 acts as an essential downstream effector of signals that trigger inflammatory responses and has been implicated in driving the onset and progression of many chronic inflammatory diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
